By: Adam Feuerstein | 04/29/14 - 04:26 PM EDTSAN FRANCISCO -- I'm attending the Allicense 2014 healthcare deal-making conference organized by Thomson Reuters. The weather here today is incredible. The conference is pretty good, too! Here are some highlights from this morning's panel sessions:
@adamfeuerstein That's funny given $BMY P/E larger than $GILD, $AMGN,$BIIB, $REGN, and $CELG. David Sobek (@dsobek) April 29, 2014And this:
@adamfeuerstein Must admit, I always find that argument partly flawed; great assets/entities are valuable. Would they rather buy mediocrity? Katrine Bosley (@ksbosley) April 29, 2014Celgene deal maker George Golumbeski also participated on the panel with Brazier. Golumbeski agreed that price is a factor in Big Pharma's reluctance to acquire Big Biotech, but so too is Big Pharma's "aversion to risk". I'm sort of putting words in Golumbeski's mouth here, but he said Big Pharma is too scared (and too stupid?) to figure out buying Big Biotech would help them out a lot.
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/12/14 - 09:43 AM EDT
09/11/14 - 01:23 PM EDT
09/10/14 - 03:37 PM EDT
09/17/14 - 12:44 PM EDT
09/17/14 - 09:30 AM EDT
09/16/14 - 12:11 PM EDT
09/15/14 - 10:40 AM EDT
09/14/14 - 15:51 PM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.